

# Screening to detect high blood pressure among coastal community dwellers and link them to appropriate care

<b>Submission date</b> 01/10/2023	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 04/10/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 07/11/2024	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

In Ghana, there has been a significant rise in the number of people dealing with high blood pressure (known as hypertension) in recent years. Unfortunately, not enough people are getting diagnosed, and even when they are, their treatment isn't always as effective as it should be. This leads to more health problems and even deaths because blood pressure isn't well-managed.

This situation shows that we need to find new ways to treat hypertension, especially in areas where a lot of people are struggling with it, like in poor neighborhoods in cities. This study's goal is to find people who have hypertension in coastal communities around the Greater Accra region, make sure they get the right medical care if they're newly diagnosed, and keep an eye on how well their treatment is working. We'll be using strategies where certain healthcare tasks can be handled by different trained individuals to make this process smoother and more efficient.

### Who can participate?

The study will recruit participants with a mean blood pressure of  $\geq 140/90$ mmHg in seven coastal communities in Ghana's Greater Accra region.

### What does the study involve?

Those who are selected for this study will be connected to specific healthcare facilities and monitored for a year to see how their treatment is going. During this time, we'll check things like how well their blood pressure is controlled, if they're following their treatment plan, their physical measurements, eye health, protein in their urine, kidney function, heart's electrical activity (electrocardiogram), and heart imaging (echocardiograms).

We're also going to use mobile health technology (mHealth) to help with things like screening people in the community, checking their blood pressure, keeping an eye on diagnosed hypertensive patients from a distance, and sending messages about taking medicine and making lifestyle changes.

To understand what people know and think about diagnosing, treating, and managing hypertension, we'll have group discussions with community members and more in-depth conversations with newly diagnosed hypertensive individuals, community health workers, and religious leaders or representatives.

What are the possible benefits and risks of participating?

The study outcomes will help improve treatment and control rates and reduce the incidence of target organ damage. potential risk will stress of knowing hypertension status, and also pain from the needle prick during sampling

Where is the study run from?

Deutsche Gesellschaft für Internationale Zusammenarbeit (Germany)

When is the study starting and how long is it expected to run for?

February 2023 to October 2024

Who is funding the study?

1. Deutsche Gesellschaft für Internationale Zusammenarbeit (Germany)
2. Bayer (Germany)

Who is the main contact?

Prof Vincent Boima, vboima@ug.edu.gh

Dr Alfred Doku, adoku@ug.edu.gh

## Contact information

### Type(s)

Public, Scientific, Principal investigator

### Contact name

Prof Vincent Boima

### ORCID ID

<https://orcid.org/0000-0002-0562-6307>

### Contact details

Department of Medicine and Therapeutics  
University of Ghana Medical School/KorleBu Teaching Hospital  
College of Health Sciences  
Accra  
Ghana  
BOX 4236  
+233 244528210  
vboima@ug.edu.gh

### Type(s)

Principal investigator

### Contact name

Dr Alfred Doku

## Contact details

Department of Medicine and Therapeutics  
University of Ghana Medical School/KorleBu Teaching Hospital  
College of Health Sciences  
Accra  
Ghana  
P.O. Box 4236  
+233 244273573  
adoku@ug.edu.gh

## Additional identifiers

### Protocol serial number

68.3025.1-001

## Study information

### Scientific Title

Detection, linkage to care, treatment, and monitoring of hypertension: a quasi-experimental study in coastal communities in Accra - The Ghana Heart Initiative Hypertension study protocol

### Study objectives

Screening to detect and link hypertensive patients to care will improve the treatment rate, control rate, and reduce the incidence of hypertension-associated target organ damage

### Ethics approval required

Ethics approval required

### Ethics approval(s)

approved 27/02/2023, Ghana Health Service Ethics Review Committee (Research and Development Division, Ghana Health Service, Accra, P.O. Box MB 190, Ghana; +233 302681109; ethics.research@ghs.gov.gh), ref: GHS-ERC: 028/08/22

### Study design

Multicenter community-based quasi-experimental and qualitative study

### Primary study design

Observational

### Study type(s)

Diagnostic, Prevention, Screening, Treatment

### Health condition(s) or problem(s) studied

Detection, and treatment of hypertension and prevention of hypertension-associated target organ damage

### Interventions

Quantitative data will be collected by trained research assistants. We will screen 10,000 people in the 7 coastal communities in the Greater Accra Region to identify 3,000 people with hypertension. These patients will be linked to clinics, hospitals, and healthcare centers in their

communities or nearby communities (evaluation centers for the study). baseline data including clinical and laboratory parameters, medication adherence, ECG, and ECHO. Patients will be assessed again in 6 and 12 months respectively.

On a monthly basis before each assessment at the evaluation centers, patients will be seen by the community healthcare nurses and community pharmacists for blood pressure measurement and a refill of their medications. The data will be collected electronically using the already existing electronic data collection systems with the aid of electronic devices (tablets). The electronic database system has an e-tracker component which has been programmed to be used for sending messages to patients regarding adherence to medication and lifestyle changes. The messages will be sent twice a week throughout the study period (12 months). Patients in each health facility will be divided into the intervention arm and the control arm to receive or not receive the messages.

Both control and the intervention arm will be followed up in the 6th and 12th months of the study. Qualitative data collection will be done by trained research assistants. They will use semi-structured interview guides to conduct individual face-to-face in-depth interviews with all study participants, as well as focus group discussions with community members. To ensure privacy and confidentiality, all IDIs will be conducted one-on-one with participants in an enclosed area detached from others. In addition, participants in FGDs would be urged to respect each other's confidentiality.

### **Intervention Type**

Behavioural

### **Primary outcome(s)**

Current primary outcome measure as of 20/05/2024:

Measured at baseline, 6, and 12 months:

1. Blood pressure measured using a sphygmomanometer
2. Hypertension mediated target organ damage (HMTOD):
  - 2.1. ECG and ECHO for heart damage
  - 2.2 Creatinine, proteinuria

---

Previous primary outcome measure:

Measured at baseline, 6, and 12 months:

1. Blood pressure measured using a sphygmomanometer
2. Hypertension mediated target organ damage (HMTOD):
  - 2.1. ECG and ECHO for heart damage
  - 2.2. Proteinuria and Creatinine for kidney damage

### **Key secondary outcome(s)**

Current secondary outcome measures as of 20/05/2024:

1. Baseline prevalence of hypertension
2. The proportion of hypertensive patients linked to care in an urban coastal community in Accra measured using patient records at the end of the study
3. Medication adherence rate among hypertensive patients linked to care measured using Hill-Bone HBP Compliance to High Blood Pressure Therapy Scale (HB-HBP) at baseline, 6, and 12

months

4. The perception and lived experiences of community members on hypertension and its management measured using in-depth interviews and focus group discussions at baseline

---

Previous secondary outcome measures:

1. Proportion of hypertensive patients linked to care in an urban coastal community in Accra measured using patient records at the end of the study
2. Medication adherence rate among hypertensive patients linked to care measured using Hill-Bone HBP Compliance to High Blood Pressure Therapy Scale (HB-HBP) at baseline, 6, and 12 months
3. The perception and lived experiences of community members on hypertension and its management measured using in-depth interviews and focus group discussions at baseline

**Completion date**

04/10/2024

## Eligibility

**Key inclusion criteria**

Current inclusion criteria as of 20/05/2024:

1. Resident in the Greater Accra Region of Ghana
2. Resident in the selected urban coastal communities
3. Aged 18 years or older as of last birthday
4. Have no intention of relocating outside of the study communities prior to enrolment and during the study period
5. Have a three-time blood pressure recording with a mean of  $\geq 140/90$ mmhg at the time of recruitment
6. Newly diagnosed hypertensive; and
7. Willing to participate and has the ability to give consent.

---

Previous inclusion criteria:

Adults 18 years and above in coastal communities in the Greater Accra Region of Ghana

**Participant type(s)**

Population

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

100 years

**Sex**

All

**Key exclusion criteria**

1. Not a resident of the Greater Accra region and the selected coastal communities
2. Residents who intend to travel or re-locate before or during the study period
3. Known hypertensive participants who are already on medication
4. Known end-organ dysfunction on treatment
5. Not willing to participate in the study or do not give consent

**Date of first enrolment**

04/10/2023

**Date of final enrolment**

04/02/2024

**Locations****Countries of recruitment**

Ghana

**Study participating centre**

Greater Accra Region of Ghana

GA-076-0913

Accra

Ghana

P.O. Box M196

**Sponsor information****Organisation**

Deutsche Gesellschaft für Internationale Zusammenarbeit

**ROR**

<https://ror.org/00q08t645>

**Organisation**

Bayer (Germany)

**ROR**

https://ror.org/04hmn8g73

## Funder(s)

### Funder type

Government

### Funder Name

Deutsche Gesellschaft für Internationale Zusammenarbeit

### Funder Name

Bayer

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a publicly available repository (District Health Information Management System (DHIMS)/Ministry of Local Government, Decentralisation & Rural Development (ddd.gov.gh)

### IPD sharing plan summary

Stored in publicly available repository

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		04/11/2024	07/11/2024	Yes	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes